MACPAC held a meeting on October 31 and November 1, 2024 (link). The following relevant topics were discussed:

  • Medications for Opioid Use Disorder and Related Policies
  • Multi-Year Continuous Eligibility for Children
  • Transitions of Care for Children and Youth with Special Health Care Needs
  • Directed Payments in Medicaid Managed Care

ADVI Angle

Key takeaways from the October meeting include:

  • Staff presented research related to Medications for Opioid Use Disorder (MOUD) and factors affecting access to MOUDs. Commissioners directed staff to conduct further research on parity rules, the rates at which substance abuse providers are paid, and whether there was a connection between Medicaid expansion states and overdose rates.
  • Staff and panelists discussed research regarding Medicaid Continuous Eligibility and Enrollment (CE) periods for covered children. Commissioners asked staff for additional research on health literacy and said they want to improve Medicaid care delivery.
  • Staff presented interview and focus group findings on care transitions for Children and Youth with Special Health Care Needs (CYSHCN). Commissioners requested additional research on possible ways to improve the program. Staff noted that they may present policy options at the December 2024 MACPAC meeting.
  • Staff provided an overview of trends related to Directed Payments in Medicaid Managed Care. The Commissioners asked staff to monitor direct payment arrangements and provide more research on Medicaid hospital payments across states.

This is an abridged and delayed release. Full ADVI Analysis content is distributed in real time for retainer clients. Get in touch to learn more about how we can support your commercialization, market access, and policy needs.


Charles Sewell
Senior Associate

CEO insights

Real analysis from people who’ve been there

Cell and Gene Precision Medicine State Policy

The 2026 Rare Disease Reality

Orphan drugs now represent approximately 20 percent of total prescription spend, and over 52 percent of the cell and gene …

Marc Samuels, JD, MPH
February 26, 2026

AI in the Patient Care Paradigm: Examining Regulatory Challenges to Clinical Adoption  

Artificial intelligence could transform clinical care, but regulatory hurdles slow adoption. Ensuring healthcare AI has adequate policy safeguards is paramount …

Marc Samuels, JD, MPH
December 30, 2025

Precision Medicine

2026 Life Sciences Forecast: AI, Next-Gen Cell & Gene Therapy, and Policy Disruption

In 2026, we expect the healthcare landscape to be defined by technology breakthroughs, market access disruption, and profound policy changes. …

Marc Samuels, JD, MPH
December 16, 2025

Cell and Gene

Delivering on CAR T-cell Therapy’s Promise: Policy Solutions for the Next Era of Cancer Care

CAR T-cell therapy offers a groundbreaking treatment option for patients with relapsed or refractory hematologic malignancies, yet access remains severely …

Alicia Silver, MPP
November 21, 2025

Inflation Reduction Act Pharmaceuticals and Biotech

Why is Medicare Data Central to IRA Negotiations?

The Inflation Reduction Act (IRA), passed in 2022, has transformed the way drug pricing will be managed in the United …

September 10, 2025

Rare Disease

The Unintended Consequences of Drug Pricing Policies on Orphan Drug Development

Rare diseases impact nearly 1 in 10 people in the US and are largely untreated, with 95 percent lacking FDA-approved …

Tyler Seville, MPA
June 23, 2025

State Policy

ADVI Analysis: HRSA 340B Covered Entity Audits

Analysis of HRSA 340B Covered Entity Audits Since the 340B Drug Pricing Program began in 1992, covered entities’ participation has …

March 10, 2025

ADVI Angle Vertical

Rare Disease State Policy

Prescription Drug Affordability Boards: Access Concerns and Implications for Rare Diseases and Conditions

In recent years, states have increasingly enacted Prescription Drug Affordability Boards (PDABs). While their stated purpose is to increase affordability, …

Allison Schneider, MHA
February 28, 2025

Reach out

Own your edge

We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.